drugset / Trial / NCT00674674

Phase 1 Intrathecal Topotecan for Neoplastic Meningitis

NCT00674674

Non-randomizedSingle-groupOpen-labelSupportive care

Summary

1. To find the optimal dose of topotecan that can safely be given directly into the spinal fluid (called intrathecal administration) of children whose cancer has spread to the lining of the brain and/or spinal cord. 2. To find out what effects (good and bad) topotecan has when given directly into the cerebrospinal fluid in children with neoplastic meningitis (cancer that has spread to the lining of the brain and spinal cord). * Cerebrospinal fluid is the fluid that circulates around the brain and spinal cord. 3. To determine if intrathecal topotecan is beneficial to patients. 4. To better understand how topotecan is handled by the body after intrathecal administration. 5. To evaluate the cerebrospinal fluid for signs (markers) of tumor spread.

Timeline

Start
2005-10
Primary completion
2010-08
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Topotecan Small molecule Intrathecal

Indications